Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Antibacterial R&D incentives

Nature Reviews Drug Discovery volume 10, pages 727–728 (2011)Cite this article

Subjects

Stimulating antibacterial R&D

New antibacterial drugs should fulfil three criteria: first, they should be drugs to which resistance has not developed and that do not exhibit cross-resistance with other drugs; second, they should have a narrow spectrum of activity to reduce the likelihood of resistance; and third, they should directly address public health needs. The following policies to create incentives for antibacterial R&D vary substantially in their ability to meet these three objectives (Table 1).

Table 1 Policy options to encourage new antibacterial development
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Infectious Diseases Society of America. The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081–1083 (2010).

  2. Laxminarayan, R. et al. Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance (Resources for the Future, Washington DC, 2007).

    Google Scholar 

  3. Kesselheim, A. S. & Outterson, K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff. 29, 1689–1696 (2010).

    Article  Google Scholar 

  4. Dagan, R. & Klugman, K. P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 8, 785–795 (2008).

    Article  Google Scholar 

  5. Powers, J. H. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs. Clin. Infect. Dis. 45, S153–S162 (2007).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ramanan Laxminarayan is at the Center for Disease Dynamics, Economics & Policy, 1616 P St., NW Ste 600, Washington, DC 20036, USA,

    Ramanan Laxminarayan

  2. and Princeton University, Princeton, New Jersey 08544, USA.,

    Ramanan Laxminarayan

  3. John H. Powers is Associate Clinical Professor of Medicine at George Washington University School of Medicine, 18511 Fiddleleaf Terrace, Olney, Maryland 20832, USA.,

    John H. Powers

Authors
  1. Ramanan Laxminarayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John H. Powers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ramanan Laxminarayan or John H. Powers.

Ethics declarations

Competing interests

John H. Powers has acted as a consultant for the following companies: Advanced Life Sciences; AstraZeneca Pharmaceuticals, Basilea Pharmaceutica, Endo Pharmaceuticals, Exela, Gilead, Great Lakes Pharmaceuticals, Johnson & Johnson, LEO Pharma, Merck and Co, MethylGene, Novartis, Optimer, Pfizer, Pharming Group, Phico Therapeutics, Trius Pharmaceuticals, Warner Chilcott, and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laxminarayan, R., Powers, J. Antibacterial R&D incentives. Nat Rev Drug Discov 10, 727–728 (2011). https://doi.org/10.1038/nrd3560

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3560

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research